Hydrotalcite

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Hydrotalcite
Accession Number
DB13322
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
17432CG1KU
CAS number
12304-65-3
Weight
Average: 619.973
Monoisotopic: 617.940176
Chemical Formula
CH24Al2Mg6O24
InChI Key
BEBILBPAQKONJS-UHFFFAOYSA-L
InChI
InChI=1S/CH2O3.2Al.6Mg.12H2O.9O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;;;12*1H2;;;;;;;;;/q;2*+3;6*+2;;;;;;;;;;;;;9*-2/p-2
IUPAC Name
dialuminium(3+) ion hexamagnesium(2+) ion dodecahydrate carbonate nonaoxidandiide
SMILES
O.O.O.O.O.O.O.O.O.O.O.O.[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[O-]C([O-])=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Hydrotalcite.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Hydrotalcite.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineHydrotalcite may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineHydrotalcite may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineHydrotalcite may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineHydrotalcite may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Hydrotalcite.Experimental, Illicit
AcepromazineHydrotalcite can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineHydrotalcite can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Hydrotalcite.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Hydrotalcite.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Hydrotalcite.Approved
AlimemazineHydrotalcite can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolHydrotalcite can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Hydrotalcite.Approved
AmphetamineHydrotalcite may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Hydrotalcite.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Hydrotalcite.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Hydrotalcite.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Hydrotalcite.Investigational
AtazanavirHydrotalcite can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Hydrotalcite.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Hydrotalcite.Approved, Investigational
BenzphetamineHydrotalcite may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Hydrotalcite.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Hydrotalcite.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Hydrotalcite.Approved, Investigational
BL-1020Hydrotalcite can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Hydrotalcite.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Hydrotalcite.Approved
CaptoprilHydrotalcite can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Hydrotalcite.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Hydrotalcite.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Hydrotalcite.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Hydrotalcite.Approved, Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Hydrotalcite.Approved, Investigational, Vet Approved
ChlorphentermineHydrotalcite may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineHydrotalcite can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineHydrotalcite can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlortetracyclineHydrotalcite can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Hydrotalcite.Approved, Investigational
CinoxacinHydrotalcite can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Hydrotalcite.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Hydrotalcite.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Hydrotalcite.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Hydrotalcite.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Hydrotalcite.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Hydrotalcite.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Hydrotalcite.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Hydrotalcite.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Hydrotalcite.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Hydrotalcite.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Hydrotalcite.Approved, Investigational
DasatinibHydrotalcite can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Hydrotalcite.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Hydrotalcite.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Hydrotalcite.Approved
DemeclocyclineHydrotalcite can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Hydrotalcite.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Hydrotalcite.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Hydrotalcite.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Hydrotalcite.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Hydrotalcite.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Hydrotalcite.Vet Approved
DexmethylphenidateHydrotalcite can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineHydrotalcite may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionHydrotalcite may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Hydrotalcite.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Hydrotalcite.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Hydrotalcite.Approved
Dipotassium phosphateHydrotalcite can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Hydrotalcite.Approved
DoxycyclineHydrotalcite can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Hydrotalcite.Approved
EnoxacinHydrotalcite can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Hydrotalcite.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Hydrotalcite.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Hydrotalcite.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Hydrotalcite.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Hydrotalcite.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Hydrotalcite.Approved
Ferric CarboxymaltoseHydrotalcite can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateHydrotalcite can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Hydrotalcite.Approved, Investigational
FleroxacinHydrotalcite can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluasteroneThe bioavailability of Fluasterone can be decreased when combined with Hydrotalcite.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Hydrotalcite.Approved, Investigational
FlumequineHydrotalcite can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Hydrotalcite.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Hydrotalcite.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Hydrotalcite.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Hydrotalcite.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Hydrotalcite.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Hydrotalcite.Approved, Investigational
FluphenazineHydrotalcite can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Hydrotalcite.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Hydrotalcite.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Hydrotalcite.Approved
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Hydrotalcite.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Hydrotalcite.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Hydrotalcite.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Hydrotalcite.Approved, Investigational, Withdrawn
FosinoprilHydrotalcite can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Hydrotalcite.Approved, Investigational
GarenoxacinHydrotalcite can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinHydrotalcite can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Hydrotalcite.Approved, Investigational
GemifloxacinHydrotalcite can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineHydrotalcite may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinHydrotalcite can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Hydrotalcite.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Hydrotalcite.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Hydrotalcite.Approved, Vet Approved
HydroxyamphetamineHydrotalcite may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Hydrotalcite.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Hydrotalcite.Approved, Investigational
Iofetamine I-123Hydrotalcite may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronHydrotalcite can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranHydrotalcite can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateHydrotalcite can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidHydrotalcite can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Hydrotalcite.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Hydrotalcite.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Hydrotalcite.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Hydrotalcite.Approved
LevofloxacinHydrotalcite can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineHydrotalcite may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Hydrotalcite.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Hydrotalcite.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Hydrotalcite.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Hydrotalcite.Approved, Investigational
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Hydrotalcite.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Hydrotalcite.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Hydrotalcite.Approved, Investigational
MephedroneHydrotalcite may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineHydrotalcite may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Hydrotalcite.Approved
MesoridazineHydrotalcite can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineHydrotalcite may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Hydrotalcite.Approved, Vet Approved
MethotrimeprazineHydrotalcite can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethoxyphenamineHydrotalcite may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueHydrotalcite can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateHydrotalcite can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Hydrotalcite.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Hydrotalcite.Experimental
MidomafetamineHydrotalcite may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineHydrotalcite can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Hydrotalcite is combined with Misoprostol.Approved
MMDAHydrotalcite may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Hydrotalcite.Approved, Vet Approved
MoricizineHydrotalcite can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Mycophenolic acidHydrotalcite can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidHydrotalcite can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Hydrotalcite.Investigational
NemonoxacinHydrotalcite can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Hydrotalcite.Approved, Investigational
NorfloxacinHydrotalcite can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Hydrotalcite.Investigational
Oxolinic acidHydrotalcite can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Hydrotalcite.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Hydrotalcite.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Hydrotalcite.Approved
PazufloxacinHydrotalcite can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinHydrotalcite can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Hydrotalcite.Approved
PerazineHydrotalcite can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerphenazineHydrotalcite can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineHydrotalcite may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidHydrotalcite can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidHydrotalcite can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Hydrotalcite.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Hydrotalcite.Approved, Investigational, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Hydrotalcite.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Hydrotalcite.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Hydrotalcite.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Hydrotalcite.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Hydrotalcite.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
ProchlorperazineHydrotalcite can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineHydrotalcite can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineHydrotalcite can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropericiazineHydrotalcite can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiopromazineHydrotalcite can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinHydrotalcite can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineHydrotalcite may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineHydrotalcite may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Hydrotalcite.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Hydrotalcite.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Hydrotalcite.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Hydrotalcite.Approved, Investigational
RitobegronHydrotalcite may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinHydrotalcite can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Hydrotalcite.Approved
RufloxacinHydrotalcite can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Hydrotalcite.Approved
SitafloxacinHydrotalcite can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateHydrotalcite can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateHydrotalcite can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Hydrotalcite.Approved
SparfloxacinHydrotalcite can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Hydrotalcite.Approved, Investigational
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Hydrotalcite.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Hydrotalcite.Approved
TemafloxacinHydrotalcite can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThiazinamHydrotalcite can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineHydrotalcite can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineHydrotalcite can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineHydrotalcite can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Hydrotalcite.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Hydrotalcite.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Hydrotalcite is combined with Tolevamer.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Hydrotalcite.Approved, Vet Approved
TriethylenetetramineHydrotalcite can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluoperazineHydrotalcite can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriflupromazineHydrotalcite can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinHydrotalcite can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Hydrotalcite.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Hydrotalcite.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
32698917
Wikipedia
Hydrotalcite
ATC Codes
A02AD04 — Hydrotalcite

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentHeartburn1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility51.2 mg/mLALOGPS
logP1.84ALOGPS
logP0.25ChemAxon
logS-0.93ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.19 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity31.17 m3·mol-1ChemAxon
Polarizability3.52 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic carbonic acids and derivatives
Sub Class
Organic carbonic acids
Direct Parent
Organic carbonic acids
Alternative Parents
Carbonate salts / Organic oxides / Organic aluminium salts / Hydrocarbon derivatives / Carbonyl compounds / Organic cations
Substituents
Carbonate salt / Carbonic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic aluminium salt / Organic salt / Organooxygen compound / Carbonyl group / Organic cation
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:39 / Updated on March 02, 2018 04:23